Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab

The use of immune checkpoint inhibitors to treat urothelial carcinoma (UC) is increasing rapidly without clear guidance for validated risk stratification. This multicenter retrospective study collected clinicopathological information on 463 patients, and 11 predefined variables were analyzed to deve...

Descripción completa

Detalles Bibliográficos
Autores principales: Kobayashi, Takashi, Ito, Katsuhiro, Kojima, Takahiro, Kato, Minoru, Kanda, Souhei, Hatakeyama, Shingo, Matsui, Yoshiyuki, Matsushita, Yuto, Naito, Sei, Shiga, Masanobu, Miyake, Makito, Muro, Yusuke, Nakanishi, Shotaro, Kato, Yoichiro, Shibuya, Tadamasa, Hayashi, Tetsutaro, Yasumoto, Hiroaki, Yoshida, Takashi, Uemura, Motohide, Taoka, Rikiya, Kamiyama, Manabu, Ogawa, Osamu, Kitamura, Hiroshi, Nishiyama, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893997/
https://www.ncbi.nlm.nih.gov/pubmed/33283385
http://dx.doi.org/10.1111/cas.14762

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7893997/
https://www.ncbi.nlm.nih.gov/pubmed/33283385
http://dx.doi.org/10.1111/cas.14762

Ejemplares similares